D02.22
Carcinoma in situ of left bronchus and lung
Clinical Classification Guidelines
Medical Intelligence & Overview
Carcinoma in situ (CIS) of the left bronchus and lung is an early stage of cancer that originates in the cells lining the airways of the lung on the left side. 'In situ' indicates that the abnormal cells have not yet invaded neighboring tissues or spread to other parts of the body. This condition is considered a pre-invasive form of lung cancer, making early detection and management crucial. Although it is confined to a specific region, CIS must be carefully monitored and treated to prevent progression to invasive lung cancer.
Causes & Symptoms
Clinical Causes: Long-term exposure to tobacco smoke is the primary risk factor. Exposure to environmental pollutants such as radon, asbestos, and air pollution. History of previous lung diseases, including chronic bronchitis and other respiratory conditions. Genetic predispositions that may increase susceptibility to cellular abnormalities in lung tissues. Occupational exposures involving inhalation of carcinogenic substances.
Key Symptoms: Persistent coughing that does not improve over time. Shortness of breath or wheezing. Chest discomfort or pain. Recurrent respiratory infections. Coughing up small amounts of blood or blood-stained sputum. Unexplained weight loss or fatigue in some cases.
Diagnostic & Treatment
Diagnosis Path: Diagnosis typically involves a combination of imaging tests and tissue sampling. Common procedures include: - **Imaging Tests:** Chest X-rays and CT scans are used to identify abnormal areas in the lung. - **Bronchoscopy:** A procedure where a flexible tube with a camera is inserted into the airways to visualize and obtain tissue samples. - **Biopsy:** Extraction of a small tissue sample for microscopic examination confirms the presence of carcinoma in situ. - **Histopathological Analysis:** Laboratory analysis of the tissue to assess cellular abnormalities and rule out invasive cancer.
Treatment Protocols: Management of carcinoma in situ of the lung involves options aimed at removing or destroying abnormal cells and preventing progression. These include: - **Surgical Removal:** Resection of the affected segment of the lung or bronchus to eliminate abnormal tissue. - **Endobronchial Therapy:** Techniques like laser therapy, photodynamic therapy, or electrocautery to destroy localized lesions. - **Radiation Therapy:** Targeted radiation to eliminate abnormal cells, especially if surgery is not viable. - **Regular Monitoring:** Close follow-up with imaging and bronchoscopy to observe for changes or progression. Early treatment of CIS significantly improves the prognosis and reduces the risk of developing invasive lung cancer.
Clinical Advice & FAQs
Billing Guidance
Is D02.22 a billable ICD-10 code?
Yes, D02.22 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D02.22?
Clinical documentation must specify the nature of Carcinoma in situ of left bronchus and lung and any associated comorbidities for accurate reporting.
Cite this Clinical Reference